atrasentan has been researched along with empagliflozin in 2 studies
| Studies (atrasentan) | Trials (atrasentan) | Recent Studies (post-2010) (atrasentan) | Studies (empagliflozin) | Trials (empagliflozin) | Recent Studies (post-2010) (empagliflozin) |
|---|---|---|---|---|---|
| 358 | 41 | 108 | 1,429 | 313 | 1,395 |
| Protein | Taxonomy | atrasentan (IC50) | empagliflozin (IC50) |
|---|---|---|---|
| Sodium/glucose cotransporter 2 | Homo sapiens (human) | 0.0031 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Breyer, MD; Susztak, K | 1 |
| Benito, B; Bermejo, S; Dominguez-Báez, P; Jacobs-Cacha, C; Llorens-Cebria, C; Martinez-Diaz, I; Martos, N; Ortiz, A; Pieper, MP; Soler, MJ; Van den Bosch, MM; Vergara, A | 1 |
1 review(s) available for atrasentan and empagliflozin
| Article | Year |
|---|---|
Developing Treatments for Chronic Kidney Disease in the 21st Century.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Atrasentan; Benzhydryl Compounds; Canagliflozin; Diabetic Nephropathies; Drug Discovery; Endothelin Receptor Antagonists; Glucosides; Glycosaminoglycans; Humans; Hypoglycemic Agents; Mineralocorticoid Receptor Antagonists; Oleanolic Acid; Oxidative Stress; Pyridoxamine; Pyrrolidines; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
1 other study(ies) available for atrasentan and empagliflozin
| Article | Year |
|---|---|
Enhanced Cardiorenal Protective Effects of Combining SGLT2 Inhibition, Endothelin Receptor Antagonism and RAS Blockade in Type 2 Diabetic Mice.
Topics: Animals; Atrasentan; Blood Glucose; Diabetes Mellitus, Type 2; Endothelin Receptor Antagonists; Mice; Ramipril; Receptors, Endothelin; Renin-Angiotensin System; Sodium-Glucose Transporter 2 | 2022 |